Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Small Cell Lung Carcinoma 24Neoplasms 7Sarcoma 4Ovarian Neoplasms 4Lung Neoplasms 4Breast Neoplasms 4Sarcoma, Ewing 3Neuroendocrine Tumors 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Advanced Solid Tumor 3Neoplasm Metastasis 2Mesothelioma 2Desmoplastic Small Round Cell Tumor 2Colorectal Neoplasms 2Advanced Solid Tumors 2Stomach Neoplasms 1Solid Tumors 1SCLC, Extensive Stage 1Recurrence 1Platinum-Resistant Lung Small Cell Carcinoma 1Pancreatic Neoplasms 1Neutropenia 1Mesothelioma, Malignant 1Major Advanced Solid Tumors Other Than Colorectal 1Leukemia 1Leiomyosarcoma 1Glioblastoma 1Gastrointestinal Malignancies 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Injections 27Carboplatin 18Docetaxel 14pembrolizumab 13Paclitaxel 12Bevacizumab 10durvalumab 8Nivolumab 8Cisplatin 8Fluorouracil 7Pemetrexed 6Oxaliplatin 6Leucovorin 6trifluridine tipiracil drug combination 5toripalimab 5tislelizumab 5linifanib 5Capecitabine 5zimberelimab 4talazoparib 4olaparib 4fludarabine 4Panobinostat 4Itraconazole 4Irinotecan 4Gemcitabine 4Everolimus 4tremelimumab 3sotorasib 3sintilimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Advanced Solid Tumors × PM 01183 × Clear all
NCT05063318 2025-09-02

Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors

PharmaMar

Phase 1 Completed
14 enrolled 20 charts
Other solid neoplasm

Advanced Solid Tumors

NCT02454972 2023-03-02

Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors

PharmaMar

Phase 2 Completed
345 enrolled 34 charts 1 FDA
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡